Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00186290 · ClinicalTrials.gov registry record · NA
Allo BMT in Advanced Leukemia or High Grade Lymphoma
A NA study, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 145
- Enrollment target
NCT00186290: Completed NA study, sponsored by Stanford University.
NCT00186290 is a NA study that has completed, run by Stanford University. The registered enrollment target is 145 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00186290, a NA study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 145 participants
- Enrollment target
Study Summary
To evaluate the role of ablative allogeneic hematopoietic cell transplantation in the treatment of advanced leukemia or lymphoma.
Interventions
- PROCEDURE ablative allogeneic hematopoietic cell transplantation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 145 participants |
| Start Date | 1989-12 |
| Est. Completion | 2009-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00186290
The ClinicalTrials.gov registry entry for NCT00186290 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 145 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ablative allogeneic hematopoietic cell transplantation is the first listed.
NCT00186290 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00186290 about?
NCT00186290 is a clinical study titled "Allo BMT in Advanced Leukemia or High Grade Lymphoma". To evaluate the role of ablative allogeneic hematopoietic cell transplantation in the treatment of advanced leukemia or lymphoma.
What is the current status of trial NCT00186290?
This trial is currently completed. It is a NA study. The enrollment target is 145 participants. The study started on 1989-12. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00186290?
The interventions under investigation include: ablative allogeneic hematopoietic cell transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT00186290?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.